Ten-year survival has been reported to be as low as 20 percent. But a Loyola University Medical Center study has found survival is not as dismal as prior reports.
READ FULL ARTICLE
From Medical Express
Mesenchymal chondrosarcoma remains classified among the more deadly cancer types, but a recent study has indicated that survival for this disease may not be as low as was previously thought.
A Loyola University Medical Center study, led by senior author Lukas Nystrom, MD, reviewed survival for 205 individuals with mesenchymal chondrosarcoma (cases occurring between 1973 and 2011).
Data was sourced from the Surveillance, Epidemiology and End Results (SEER) program database, which is administered through the National Cancer Institute (NCI). Fifty-one percent survived a minimum of 5 years, and 43 percent survived 10 years or more. survival rates observed differed, depending on the tumor location: an axial location demonstrated a lower survival rate.
Dr. Nystrom has suggested that this lower survival outcome could be attributable to the inoperable location of the axial tumors.
Improved screening techniques and technology could be a factor in the lowering (if still high) mortality rates overall.
Ten-year survival has been reported to be as low as 20 percent. But a Loyola University Medical Center study has found survival is not as dismal as prior reports.
READ FULL ARTICLE
From Medical Express
Enjoying our content?
Thanks for visiting Oncology Nurse Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Oncology Nurse Advisor. Register for free and gain unlimited access to:
- Clinical Updates
- Evidence-Based Guidance
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Please login or register first to view this content.